Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J CURIEL

Showing results (121-130 of 150) with videos related to

Pageof 15
Sort By:
International Journal of Oncology|May 13, 2004
Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signalingChristopher B Weldon, Amanda P Parker, Daniel Patten, et al.
Journal for Immunotherapy of Cancer|April 14, 2021
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activationRyan Michael Reyes, Yilun Deng, Deyi Zhang, et al.
Experimental Parasitology|April 2, 2013
TgMAPK1 is a Toxoplasma gondii MAP kinase that hijacks host MKK3 signals to regulate virulence and interferon-γ-mediated nitric oxide productionMichael J Brumlik, Srilakshmi Pandeswara, Sara M Ludwig, et al.
The Journal of Clinical Investigation|June 25, 2014
A phosphotyrosine switch determines the antitumor activity of ERβBin Yuan, Long Cheng, Huai-Chin Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2016
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic TargetAlfredo Perales-Puchalt, Nikolaos Svoronos, Melanie R Rutkowski, et al.
Molecular Endocrinology (Baltimore, Md.)|January 18, 2006
p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1Daniel E Frigo, Aninda Basu, Erica N Nierth-Simpson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesisVirgilo A Salvo, Stephen M Boué, Juan P Fonseca, et al.
Nature Medicine|August 24, 2004
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalTyler J Curiel, George Coukos, Linhua Zou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerChristophe Massard, Michael S Gordon, Sunil Sharma, et al.
Nature Medicine|April 22, 2003
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunityTyler J Curiel, Shuang Wei, Haidong Dong, et al.
Pageof 15

Showing results (121-130 of 150) with videos related to

Sort By:
Pageof 15
International Journal of Oncology|May 13, 2004
Sensitization of apoptotically-resistant breast carcinoma cells to TNF and TRAIL by inhibition of p38 mitogen-activated protein kinase signalingChristopher B Weldon, Amanda P Parker, Daniel Patten, et al.
Journal for Immunotherapy of Cancer|April 14, 2021
CD122-directed interleukin-2 treatment mechanisms in bladder cancer differ from αPD-L1 and include tissue-selective γδ T cell activationRyan Michael Reyes, Yilun Deng, Deyi Zhang, et al.
Experimental Parasitology|April 2, 2013
TgMAPK1 is a Toxoplasma gondii MAP kinase that hijacks host MKK3 signals to regulate virulence and interferon-γ-mediated nitric oxide productionMichael J Brumlik, Srilakshmi Pandeswara, Sara M Ludwig, et al.
The Journal of Clinical Investigation|June 25, 2014
A phosphotyrosine switch determines the antitumor activity of ERβBin Yuan, Long Cheng, Huai-Chin Chiang, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2016
Follicle-Stimulating Hormone Receptor Is Expressed by Most Ovarian Cancer Subtypes and Is a Safe and Effective Immunotherapeutic TargetAlfredo Perales-Puchalt, Nikolaos Svoronos, Melanie R Rutkowski, et al.
Molecular Endocrinology (Baltimore, Md.)|January 18, 2006
p38 mitogen-activated protein kinase stimulates estrogen-mediated transcription and proliferation through the phosphorylation and potentiation of the p160 coactivator glucocorticoid receptor-interacting protein 1Daniel E Frigo, Aninda Basu, Erica N Nierth-Simpson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 6, 2006
Antiestrogenic glyceollins suppress human breast and ovarian carcinoma tumorigenesisVirgilo A Salvo, Stephen M Boué, Juan P Fonseca, et al.
Nature Medicine|August 24, 2004
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survivalTyler J Curiel, George Coukos, Linhua Zou, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 9, 2016
Safety and Efficacy of Durvalumab (MEDI4736), an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder CancerChristophe Massard, Michael S Gordon, Sunil Sharma, et al.
Nature Medicine|April 22, 2003
Blockade of B7-H1 improves myeloid dendritic cell-mediated antitumor immunityTyler J Curiel, Shuang Wei, Haidong Dong, et al.
Pageof 15